Intellia falls as mid-stage data from gene therapy study fails to impress

BioCryst Pharmaceuticals

24/10/2024 15:31

** Gene editing firm Intellia Therapeutics'  NTLA.O  shares
fall 18% to $16.38
    ** Company says its experimental gene therapy to treat a
rare disorder called hereditary angioedema (HAE) helped reduce
monthly swelling attacks by up to 81% vs placebo in a mid-stage
study
    ** HAE is characterized by unpredictable and frequent severe
swelling of the skin, gastrointestinal tract, upper respiratory
system, face and throat
    ** "We expect investors will view the ~75-80% reduction in
HAE attacks as less than impressive in the context of the
potential risks of in vivo gene editing and the competitive
landscape in this indication" - brokerage Baird
    ** HAE treatments in the U.S. that are currently approved
include drugs made by Takeda Pharmaceuticals  4502.T  and
BioCryst Pharmaceuticals  BCRX.O 
    ** Including session moves, Intellia shares down ~46% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com))